Related references
Note: Only part of the references are listed.Nitric oxide and redox mechanisms in the immune response
David A. Wink et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Ronald S. Black et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2010)
Matrix Metalloproteinase 2 (MMP-2) Degrades Soluble Vasculotropic Amyloid-β E22Q and L34V Mutants, Delaying Their Toxicity for Human Brain Microvascular Endothelial Cells
Mar Hernandez-Guillamon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
Donna M. Wilcock et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2009)
A TLR2 Agonist in German Cockroach Frass Activates MMP-9 Release and Is Protective against Allergic Inflammation in Mice
Kristen Page et al.
JOURNAL OF IMMUNOLOGY (2009)
Amyloid Reduction by Amyloid-β Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease
Donna M. Wilcock et al.
JOURNAL OF NEUROSCIENCE (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
DIVERSE ROLES OF MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN NEUROINFLAMMATION AND CEREBRAL ISCHEMIA
E. Candelario-Jalil et al.
NEUROSCIENCE (2009)
Immunotherapy reduces vascular amyloid-β in PDAPP mice
Sally Schroeter et al.
JOURNAL OF NEUROSCIENCE (2008)
Prevalence and risk factors of cerebral microbleeds - The Rotterdam Scan Study
M. W. Vernooij et al.
NEUROLOGY (2008)
MMP-2,-3 and-9 levels and activity are not related to Aβ load in the frontal cortex in Alzheimer's disease
S. Baig et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2008)
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice
Y. Suzuki et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ
Ping Yan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils
S Chakrabarti et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for Alzheimer therapeutics
D Morgan et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration
DM Wilcock et al.
NEUROBIOLOGY OF DISEASE (2004)
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition
DM Wilcock et al.
JOURNAL OF NEUROSCIENCE (2004)
Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy
JM Lee et al.
ANNALS OF NEUROLOGY (2003)
Cerebral hemorrhage after passive anti-Aβ immunotherapy
M Pfeifer et al.
SCIENCE (2002)
The tumor necrosis factor-α converting enzyme (TACE):: A unique metalloproteinase with highly defined substrate selectivity
MJ Mohan et al.
BIOCHEMISTRY (2002)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats
T Sumii et al.
STROKE (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels
DM Wilcock et al.
DNA AND CELL BIOLOGY (2001)
Share Paper
